Del Labs sales and earnings
This article was originally published in The Tan Sheet
Executive SummaryNet sales jump 12.8% to $332.7 mil. in 2001, driven in part by "double-digit sales increases" in Orajel line, strong gains in cosmetics segment, firm announces Feb. 21. Also, Dermarest "continues as the number one brand of OTC psoriasis treatments," Uniondale, N.Y.-based Del notes. Net earnings more than doubled to $9.8 mil. for the year. Fourth quarter sales were up 16.4% to $85.7 mil., while earnings soared 149.6% to $2.8 mil...
You may also be interested in...
ICER president Steve Pearson is ‘cautiously optimistic’ that net pricing for acute migraine treatments will align with benefits once discounts are factored in.
Almost 50 novel agents are already under review at FDA for potential 2020 approval. Candidates are notably diverse, with concentrations in established strongholds (oncology, neuroscience), popular programs (breakthrough), and powerhouse sponsors (keep an eye on Bristol-Myers Squibb right out of the gate).
CBER is starting the year with four novel gene and cell therapy applications under review and rolling submissions underway for more.